AveXis’ (AVXS) Buy Rating Reiterated at Chardan Capital
AveXis, Inc. (NASDAQ:AVXS)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report released on Friday, Marketbeat reports. They currently have a $130.00 target price on the stock, up from their previous target price of $102.50. Chardan Capital’s target price suggests a potential upside of 45.27% from the company’s current price.
Several other research analysts also recently commented on AVXS. Jefferies Group LLC reissued a “buy” rating and set a $92.00 target price on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. started coverage on AveXis in a research note on Tuesday, May 23rd. They set a “buy” rating and a $90.00 target price for the company. BMO Capital Markets reissued an “outperform” rating and set a $95.00 target price on shares of AveXis in a research note on Friday, June 16th. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Sanford C. Bernstein started coverage on AveXis in a research note on Thursday, July 27th. They set an “outperform” rating and a $108.00 target price for the company. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $100.70.
AveXis (NASDAQ:AVXS) opened at 89.49 on Friday. The stock’s market capitalization is $2.48 billion. AveXis has a 12 month low of $31.55 and a 12 month high of $97.77. The company’s 50-day moving average is $85.66 and its 200-day moving average is $73.89.
AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same period in the previous year, the business earned ($0.68) earnings per share. Equities analysts anticipate that AveXis will post ($5.21) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/11/avexis-inc-nasdaqavxs-price-target-raised-to-130-00.html.
In other news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $81.88, for a total transaction of $145,746.40. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $145,746.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 5,340 shares of company stock worth $434,872. Company insiders own 18.60% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in AveXis during the fourth quarter valued at $1,193,000. Teachers Advisors LLC boosted its stake in AveXis by 602.2% in the fourth quarter. Teachers Advisors LLC now owns 52,830 shares of the company’s stock valued at $2,522,000 after buying an additional 45,306 shares during the period. Quantitative Systematic Strategies LLC purchased a new stake in AveXis during the first quarter valued at $201,000. Candriam Luxembourg S.C.A. purchased a new stake in AveXis during the first quarter valued at $1,901,000. Finally, Nationwide Fund Advisors boosted its stake in AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares during the period. Institutional investors own 91.85% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.